Contents
Patent expiry arbitrage is a market entry strategy that exploits the moment legal protection on a proven product lapses, allowing new entrants to manufacture, improve, or rebrand the same underlying technology — typically at lower cost or with superior distribution.
Section 1
How It Works
Every patent is a ticking clock. For up to 20 years, a patent grants its holder a legal monopoly — the right to exclude competitors from making, using, or selling a specific invention. During that window, the patent holder captures monopoly rents: pricing power unchecked by competition, margins that reflect exclusivity rather than cost of production. When the clock runs out, that monopoly evaporates overnight. The underlying technology enters the public domain, and anyone can manufacture it.
The cognitive shift this framework demands is simple: stop looking for things to invent and start looking for things that are about to become unprotected. The patent system itself is your deal flow engine. Every granted patent has a public expiration date. The FDA publishes lists of drug patents approaching expiry through its Orange Book. The USPTO maintains searchable databases. The information is free, the timing is predictable, and the demand has already been validated — often by billions of dollars in annual sales.
The underlying principle is that patent-protected products create artificially suppressed supply. Consumers who want the product but can't afford the monopoly price represent latent demand. When the patent expires, that demand doesn't need to be created — it needs to be served. The first movers who are ready with manufacturing capacity, regulatory approvals, and distribution on the day the patent lapses capture a disproportionate share of that demand release.
This is most visible in pharmaceuticals, where generic drugs routinely capture 80–90% of a branded drug's volume within a year of patent expiry. But the principle applies anywhere patents create pricing power: semiconductors, industrial chemicals, medical devices, consumer electronics components, agricultural biotechnology, and increasingly, software-adjacent hardware. The Hatch-Waxman Act of 1984 codified this dynamic in pharma by creating an abbreviated pathway for generic drug approval, but the strategic logic predates the legislation. Wherever a patent expires on a product with proven demand, the opportunity exists.
— Mark Cuban, entrepreneur and investor"The best businesses are the ones where you already know there's demand. You're not guessing — you're executing."
The mechanics vary by industry, but the playbook has three constants: identify the expiring protection, prepare your supply chain and regulatory approvals in advance, and launch the moment the window opens. The companies that win are not the ones who notice the expiry — that information is public. They're the ones who spent 18–36 months preparing so they could ship on Day One.
Section 2
When to Use This Framework
✓
Best Conditions for Patent Expiry Arbitrage
| Dimension | Ideal conditions |
|---|---|
| Founder profile | Operators with regulatory expertise and supply chain access. You need someone who understands FDA filings, manufacturing partnerships, or patent law — not a visionary product designer. Domain specialists in pharma, chemicals, medical devices, or hardware manufacturing are the ideal fit. |
| Stage | Pre-launch planning, 18–36 months before the target patent expires. The framework rewards preparation over speed. By the time the patent lapses, your product should be manufactured, approved (if applicable), and ready for distribution. Starting after expiry means you've already lost the first-mover window. |
| Market conditions | Best when the patent-protected product has high consumer awareness, significant annual revenue ($100M+), and pricing that is widely perceived as excessive. The larger the gap between production cost and retail price, the more margin available for new entrants. |
| Competitive environment | Ideal when few competitors are preparing for the same expiry window, or when the incumbent has signaled it will not aggressively defend through authorized generics, patent evergreening, or litigation. Markets where the incumbent is distracted — facing other patent cliffs, M&A activity, or pipeline problems — are especially attractive. |
| Regulatory landscape | Strongest in jurisdictions with clear abbreviated approval pathways — ANDA filings in the U.S., ABPI processes in the EU, or equivalent frameworks. Markets without streamlined generic/biosimilar approval processes dramatically increase time-to-market and reduce the advantage of early preparation. |
| Capital requirements | Moderate to high. Generic pharma requires manufacturing facilities and regulatory filings that can cost $1–5M per product. Consumer product rebrands (like Hims) require less manufacturing capital but significant marketing spend. Hardware and industrial applications vary widely. |
The framework is particularly fertile right now. Between 2024 and 2030, an estimated $250 billion in branded pharmaceutical revenue faces patent expiry, including blockbusters like Humira (adalimumab, already off-patent with biosimilars launching), Keytruda (pembrolizumab, patent expiry expected around 2028), and Eliquis (apixaban, facing patent challenges). Beyond pharma, key patents in CRISPR gene-editing technology, certain 5G communication protocols, and advanced battery chemistries are approaching expiry or facing challenges — each representing a distinct entry window for prepared operators.
Section 3
When It Misleads
⚠
Failure Modes & Blind Spots
| Blind spot | What goes wrong |
|---|---|
| Patent evergreening | The incumbent files secondary patents on formulations, delivery mechanisms, or manufacturing processes that extend effective exclusivity well beyond the original patent's expiry. AbbVie built a "patent thicket" of over 100 patents around Humira, delaying biosimilar competition in the U.S. until 2023 — nearly a decade after the core compound patent expired in Europe. |
| Authorized generics | The incumbent launches its own generic version, often through a subsidiary, cannibalizing the market before independent generics can gain traction. This is a deliberate defensive strategy — the incumbent accepts lower margins to deny volume to competitors. Pfizer did this with Lipitor through its own authorized generic. |
| Brand loyalty moats | In some categories, consumers have such strong brand attachment that generic alternatives struggle despite identical formulations. This is less common in pharma (where pharmacists and insurers drive substitution) but significant in consumer products, where the original brand's marketing spend creates switching costs that price alone can't overcome. |
| Race-to-the-bottom pricing | When dozens of generic manufacturers target the same patent expiry simultaneously, margins collapse rapidly. In commodity generics, prices can fall 90%+ within two years of expiry. If you're the fifteenth entrant with no differentiation, you're competing on manufacturing cost alone — a game won by the largest-scale producers in India and China. |
| Regulatory complexity underestimation | Filing an ANDA (Abbreviated New Drug Application) in the U.S. is not trivial — median approval times run 3–4 years, and the FDA can issue complete response letters requiring additional studies. Biosimilar approvals are even more complex, requiring clinical trials that can cost $100–200M. Founders who treat regulatory approval as a formality get burned. |
| Technology obsolescence | By the time a patent expires, the underlying technology may have been superseded. Copying a 20-year-old semiconductor design or chemical process may yield a product nobody wants because the market has moved to a newer generation. The patent expires, but so does the demand. |
The single most common mistake is treating patent expiry as the only barrier to entry. The patent is the legal barrier, but the real barriers are often manufacturing capability, regulatory approval timelines, distribution relationships, and brand trust. A patent expiring doesn't mean you can ship tomorrow — it means you can start the process of competing. The winners are the ones who started that process years before expiry day.
Section 4
Step-by-Step Process
Step 1 — ScoutTools: FDA Orange Book, USPTO Patent Full-Text Database, Drugs@FDA, Google Patents, EvaluatePharma, IPO (Intellectual Property Office) databases
Build a patent expiry pipeline
Systematically identify high-value patents expiring in the next 3–7 years. In pharma, the FDA's Orange Book lists every approved drug and its associated patents with expiry dates. For non-pharma industries, use USPTO and Google Patents to search by technology category and filing date (add 20 years for expiry). Prioritize products with annual revenue exceeding $500M, high consumer awareness, and significant price premiums over production cost. Build a ranked pipeline of 10–20 targets.
Step 2 — AnalyzeTools: Paragraph IV certification filings, ANDA pipeline databases, competitive intelligence platforms, patent litigation trackers
Map the competitive and regulatory landscape
For each target, answer three questions: How many competitors are already preparing to enter? What is the incumbent's likely defensive strategy (evergreening, authorized generics, litigation)? What is the realistic regulatory timeline in your target jurisdiction? In pharma, check Paragraph IV certification filings to see who else has filed ANDAs. In other industries, monitor patent challenge proceedings and competitor patent filings. Eliminate targets where the competitive field is already crowded or the incumbent's patent thicket is impenetrable.
Step 3 — DifferentiateDeliverable: Differentiation memo — formulation improvements, delivery innovation, brand positioning, distribution strategy
Define your value-add beyond price
Pure generic competition is a commodity game. The highest-value plays add something the original never offered: a better delivery mechanism (Hims turned generic sildenafil into a telehealth-first subscription), a new formulation (extended-release versions, combination products), superior branding and distribution (DTC channels the incumbent ignores), or a different customer segment entirely. Document your differentiation thesis — this is what separates a $10M generic manufacturer from a $1B brand.
Step 4 — PrepareTools: Contract manufacturing organizations (CMOs), regulatory consultants, ANDA/biosimilar filing specialists, distribution partners
Secure manufacturing, regulatory filings, and distribution 18–36 months before expiry
Begin regulatory filings as early as legally permitted. In the U.S., Paragraph IV ANDA filings can be submitted up to four years before patent expiry, and the first filer receives 180 days of generic exclusivity — an enormously valuable window. Secure manufacturing partnerships or build capacity. Lock in distribution agreements with pharmacies, retailers, or DTC platforms. The goal is to be ready to ship within days of the patent lapsing, not months.
Step 5 — LaunchTools: DTC marketing platforms, pharmacy benefit manager relationships, PR campaigns, pricing strategy models
Execute a coordinated market entry on Day One
Launch with aggressive pricing (typically 20–80% below the branded product), coordinated marketing that emphasizes equivalence and value, and distribution that reaches the incumbent's existing customer base. In pharma, work with pharmacy benefit managers and insurers to secure formulary placement. In consumer products, use DTC channels and social media to reach price-sensitive customers directly. The first 90 days after patent expiry determine market share for years to come.
Section 5
Questions to Ask Yourself
Discovery
What patents expiring in the next 3–7 years protect products with $500M+ in annual revenue?
Is the demand for this product growing, stable, or declining — and will it still be relevant when the patent lapses?
What is the gap between the incumbent's retail price and the estimated production cost of a generic or unbranded version?
Are there adjacent patents (formulation, delivery, manufacturing process) that could block entry even after the core patent expires?
Competitive Assessment
How many competitors have already filed ANDAs, biosimilar applications, or equivalent regulatory submissions for this product?
Has the incumbent signaled a defensive strategy — authorized generics, patent thickets, pay-for-delay settlements?
Can I realistically be among the first 3 entrants, or will I be the fifteenth generic in a commoditized market?
Is there a Paragraph IV first-filer opportunity that would grant me 180 days of generic exclusivity?
Differentiation
How can I improve upon the original — better formulation, superior delivery, modern branding, DTC distribution, or a new customer segment?
Is there a way to repackage this off-patent technology for a market the incumbent never served?
Can I build a brand around this product that transcends generic commodity status?
Execution Risk
What is the realistic regulatory approval timeline, and can I absorb a 12–24 month delay without running out of capital?
Do I have access to manufacturing capacity that meets regulatory standards (cGMP for pharma, relevant certifications for other industries)?
What happens to my unit economics if the incumbent launches an authorized generic at a lower price than I can match?
Am I prepared for patent infringement litigation, even if I believe my position is legally sound?
Section 6
Company Examples
H&
Hims & Hers
Turned generic sildenafil and finasteride into a DTC telehealth brand after Viagra and Propecia patent expiries
When Pfizer's patent on sildenafil (Viagra) expired in 2017 and Merck's patent on finasteride (Propecia) had already lapsed, the generic versions became available at a fraction of the branded price. Hims didn't just sell cheap pills — it built a telehealth-first brand that removed the stigma and friction of purchasing erectile dysfunction and hair loss treatments. The insight was that the real barrier wasn't price but embarrassment: men didn't want to visit a doctor in person for these conditions. By wrapping generic medications in a modern DTC brand with online consultations, discreet packaging, and subscription delivery, Hims created a business valued at over $1 billion at its 2021 SPAC listing. The underlying molecules were commodities; the brand and distribution model were the moat.
LC
Lannett Company
Systematic generic drug manufacturer targeting high-value patent expiries
Lannett built its entire business model around the patent expiry pipeline, manufacturing generic versions of branded drugs as soon as patents lapsed. The company focused on products with limited generic competition — targeting molecules where only 1–3 other generic manufacturers were filing, rather than crowded categories with dozens of entrants. This selectivity allowed Lannett to maintain margins above commodity generic levels. At its peak around 2015, the company generated over $600 million in annual revenue. However, Lannett also illustrates the framework's risks: increasing generic competition and pricing pressure from pharmacy benefit managers squeezed margins severely, and the company filed for Chapter 11 bankruptcy protection in 2023 — a reminder that patent expiry arbitrage without sustained differentiation is a treadmill.
M(
Mylan (now Viatris)
Built a global generics empire by systematically targeting patent expiries across therapeutic categories
Mylan became one of the world's largest generic pharmaceutical companies by industrializing the patent expiry playbook at scale. The company filed hundreds of ANDAs, built manufacturing facilities across the U.S., India, and Europe, and developed deep expertise in navigating regulatory pathways across multiple jurisdictions. Its EpiPen business — acquired from Merck KGaA in 2007 — became both its most profitable product and its most controversial, as Mylan raised the price from roughly $100 to over $600 per two-pack. The EpiPen saga illustrates a nuanced dimension of patent expiry strategy: Mylan's dominance came not just from the device's off-patent epinephrine but from the complexity of the auto-injector device itself, which created a de facto monopoly even without strong patent protection. Mylan merged with Pfizer's Upjohn division in 2020 to form Viatris, valued at approximately $12 billion.
TP
Teva Pharmaceutical
World's largest generic drug company, built on systematic first-to-file patent expiry strategy
Teva perfected the Paragraph IV first-filer strategy, consistently being among the first to challenge branded drug patents and file ANDAs. The 180-day exclusivity window granted to first filers became Teva's primary competitive advantage — during that window, only Teva and the branded manufacturer could sell the product, allowing Teva to price at a modest discount while capturing enormous volume. This strategy drove Teva to over $20 billion in annual revenue by 2016 and made it the world's largest generic pharmaceutical company by volume. The company's subsequent struggles — including a $40 billion acquisition of Allergan's generics business that proved poorly timed as U.S. generic pricing collapsed — demonstrate that even the most sophisticated patent expiry operators face systemic market risks.
KS
Kirkland Signature (Costco)
Launches store-brand versions of off-patent consumer products at steep discounts
While not a pharmaceutical example, Costco's Kirkland Signature brand applies patent expiry logic to consumer goods more broadly. When formulation patents, trade dress protections, or exclusive supplier agreements lapse on popular consumer products, Kirkland frequently launches near-identical versions at 20–40% lower prices. Kirkland's over-the-counter medications — ibuprofen, omeprazole, cetirizine — are chemically identical to their branded counterparts (Advil, Prilosec, Zyrtec) and are manufactured by the same contract manufacturers in many cases. The Kirkland brand generated an estimated $60+ billion in annual sales as of 2023, making it one of the largest consumer brands in the world. The lesson: patent expiry arbitrage doesn't require a pharmaceutical company — it requires distribution power and consumer trust.
Section 7
Adjacent Frameworks
Patent expiry arbitrage doesn't operate in isolation. Here's how it connects to the broader strategic toolkit:
Pairs well with
Recreate boring but high value consumer products with hot rebrands
Patent expiry gives you the legal right to manufacture. This framework gives you the brand strategy. Hims is the canonical example: generic sildenafil plus modern DTC branding equals a billion-dollar company. The combination is more powerful than either alone.
Pairs well with
Take something expensive and only accessible to rich people and make it accessible to everyone else
Patent-protected products are often priced for affluent consumers or well-insured patients. When the patent expires, the democratization opportunity is immediate — same product, fraction of the price, broader distribution. This pairing is the core logic of the entire generic pharmaceutical industry.
In tension with
Category creation
Patent expiry arbitrage is fundamentally about entering an existing category with a known product. Category creation asks you to build something that doesn't exist yet. They're opposing strategies — one minimizes demand risk, the other maximizes it. Use patent expiry when you want certainty; use category creation when you want ceiling.
In tension with
Invent a new sport
Inventing a new sport means creating entirely new competitive dynamics. Patent expiry arbitrage means entering a game with well-established rules. The tension is between originality and replication — both valid, but they demand different founder temperaments and risk tolerances.
Apply next
Use regulatory changes to unlock previously inaccessible domain
Once you've entered a market through patent expiry, monitor regulatory changes that could expand your addressable market further — new indications approved for off-patent drugs, changes in OTC classification, or shifts in insurance coverage that increase demand for your product.
Apply next
Sell an Identity
After establishing your generic or off-patent product, the next strategic move is to build a brand identity that transcends commodity status. Hims evolved from "cheap Viagra alternative" to "men's wellness brand." The identity layer is what prevents margin compression.
Section 8
Analyst's Take
Faster Than Normal — Editorial View
My honest read: patent expiry arbitrage is one of the most predictable opportunity-generation frameworks in business — and precisely because of that predictability, it's both more accessible and more dangerous than most founders realize.
The accessibility is obvious. Unlike most startup frameworks that require you to identify hidden demand or predict behavioral shifts, patent expiry gives you a public calendar of when monopolies end and a public record of how much revenue those monopolies generate. You can literally build a spreadsheet of opportunities ranked by revenue at risk, competitive density, and regulatory complexity. No other framework offers this level of informational clarity at the ideation stage.
The danger is equally clear: everyone else has the same spreadsheet. The FDA Orange Book is not a secret. Every generic pharmaceutical company in the world employs teams whose sole job is to monitor patent expiries and file ANDAs. The question is never "is this an opportunity?" — it's "can I capture enough of this opportunity to build a durable business before margins compress to zero?"
The founders who win here fall into two categories. The first are scale operators — companies like Teva and Mylan that industrialize the process, filing hundreds of ANDAs and winning through manufacturing efficiency and regulatory speed. This is a capital-intensive, operationally complex game that rewards experience and infrastructure. It's not a first-time founder's play.
The second — and far more interesting for the readers of this publication — are reframers. These are founders who look at an off-patent product and ask not "how do I make this cheaper?" but "how do I make this better in a way the incumbent never bothered to?" Hims didn't compete on price alone. It competed on experience, brand, and distribution channel. It turned a commodity molecule into a lifestyle brand. The generic is the ingredient; the brand is the product. That distinction is where the real value creation happens.
The biggest mistake I see is founders who target patent expiry without a differentiation thesis. If your plan is "make the same thing cheaper," you're entering a race you will lose to manufacturers in Hyderabad and Shenzhen who have lower cost structures than you ever will. The framework works best when patent expiry is your entry ticket — not your entire strategy. Use the expiry to get legal access to the technology, then build something the incumbent never would have built: a new form factor, a new distribution model, a new brand, a new customer segment.
One more thing worth noting: this framework is expanding beyond pharma. As patents expire on key technologies in batteries, semiconductors, gene editing, and advanced materials, the same playbook applies. The founders who are building patent expiry pipelines outside of pharmaceuticals right now are playing a game with far less competition and potentially larger outcomes.
Section 9
Opportunity Checklist
Score each item as yes (1 point) or no (0 points) to evaluate whether a specific patent expiry opportunity is worth pursuing.
Patent Expiry Opportunity Scorecard
The patent-protected product generates $500M+ in annual revenue, confirming substantial proven demand.
The core patent expires within 3–7 years, giving sufficient preparation time without excessive uncertainty.
No impenetrable patent thicket exists — secondary patents on formulations, delivery, or manufacturing processes are limited or challengeable.
Fewer than 5 competitors have filed regulatory applications (ANDAs, biosimilar applications) for this product.
A clear regulatory pathway exists in your target jurisdiction with a realistic approval timeline under 3 years.
You have access to manufacturing capacity that meets regulatory standards (cGMP, ISO, or equivalent).
You can articulate a differentiation thesis beyond price — better formulation, superior branding, new distribution channel, or underserved customer segment.
The incumbent has not signaled an authorized generic launch or aggressive defensive litigation strategy.
The product's demand is stable or growing — not declining due to technological obsolescence or shifting treatment paradigms.
Your capital reserves can sustain 18–36 months of preparation costs before generating revenue.
You have domain expertise or advisors with direct experience in the relevant regulatory and manufacturing environment.
Section 10
Top Resources
01
Book
Christensen applies disruption theory specifically to healthcare, with extensive analysis of how generic drugs and biosimilars disrupt branded pharmaceutical business models. The chapters on value-chain evolution in pharma are directly applicable to anyone building a patent expiry strategy. Essential for understanding why incumbents consistently fail to defend against generic entry despite having every resource advantage.
02
Book
Porter's framework for analyzing industry structure is indispensable for evaluating patent expiry opportunities. The five forces analysis tells you whether a specific post-patent market will sustain margins or collapse to commodity pricing. The sections on barriers to entry and supplier power are particularly relevant for assessing manufacturing and regulatory moats in generic markets.
03
Book
The foundational text on why incumbents struggle to respond to lower-cost entrants — which is precisely what patent expiry enables. Christensen's explanation of why rational managers at branded pharmaceutical companies consistently cede market share to generics (because the margins look unattractive relative to their existing business) is the theoretical backbone of this entire framework.
04
Book
Slywotzky's concept of value migration — how economic value flows from outdated business designs to new ones — maps perfectly onto patent expiry dynamics. When a patent lapses, value migrates from the incumbent's pricing power to the entrant's cost structure and distribution innovation. The framework for identifying where value is flowing next is directly applicable to building a patent expiry pipeline.
05
Academic paper
Porter's updated treatment of his five forces framework, with particular relevance to understanding how patent expiry reshapes industry structure. When a patent expires, the "threat of new entrants" force shifts dramatically — this essay gives you the analytical tools to predict whether that shift will create opportunity or merely redistribute thin margins among many competitors.
Why this matters next
mental modelsFirst-Mover
Hims & Hers applied the First-Mover mental model
mental modelsIntelligence
Hims & Hers applied the Intelligence mental model
mental modelsScale
Hims & Hers applied the Scale mental model
mental modelsEnvironment
Hims & Hers applied the Environment mental model
mental modelsAlternatives
Hims & Hers applied the Alternatives mental model
mental modelsCost
Hims & Hers applied the Cost mental model
Continue exploring
RRUNIAACTRND
Framework
Recent funding rounds
Analyze companies that have recently secured significant investment, identifying
Framework
Unbundling
Breaking down a bundled product or service into separate, standalone offerings,
Framework
Industry timing arbitrage
Apply newly developed technology from one industry to another that hasn't yet ad
Framework
Acqui-Deaths
Identify opportunities created when large companies acquire startups, potentiall
Framework
Three-Star reviews
Find business opportunities by analyzing moderately satisfied customers' feedbac
Framework
Niche down
Focus on a highly specific market segment or customer base, becoming a specialis
More like this, in your inbox
I send a newsletter every week — free, no spam, unsubscribe anytime.